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I. Introduction 
The objective of this study is to determine whether specific industries across countries or 
within countries are more likely to reach a stage of profitability and make a successful 
exit. In particular, we assess whether venture capital-backed firms in certain industries 
are more prone to exit via an initial public offering (IPO), be acquired, or exit through a 
leveraged buy-out.  We are also interested in analyzing whether substantial differences 
across industries and countries arise when looking separately at the success’ rate of firms 
which have received venture funding at the early seed and start-up stages, vis-à-vis firms 
that received funding at latter stages. 
To this end, we examine venture capital (VC) investments and exits in the U.S. 
and the EU-15 countries, throughout the period 1985-2008, while further classifying 
firms into distinct industries. The dimensionality of our data set allows us to uncover 
significant relationships and common factors that lead to the success of a venture capital 
company completing the exit phase.  
The comparison between the performance of VC funds in the U.S. and European 
countries has been the subject of much research over the past decade (see Black and 
Gilson (1998), Bottazi and Da Rin (2002), and Hege, Palomino and Schwienbacher 
(2009), among others).  Differences in stock market development, contract and tax 
legislation, and labor market regulations, to name a few, have been oft-cited in 
connection to the consistent underperformance of European VC funds relative to their 
American counterparts.   Even as recently as the pre-crisis period of 2005-2007, there 
have been no signs of a decrease in the profitability gap between European and U.S. 
venture capital investment (Raade and Dantas Machado (2008)).  While acknowledging 
and controlling for country-specific differences, our paper attempts to further explore if 
there exist common elements that may explain how firms in similar industries could 
achieve a similar likelihood as to the preferred exit. 
Another relevant issue that this paper addresses is that of the asymmetry in VC 
success when separately analyzing investment in seed and start-up versus more mature 
firms.  As documented by Jeng and Wells (2000), early and later stage venture capital 
investments are affected quite differently by the determinants of venture capital. In 
particular, we intend to find out if the sub-par returns generated by European early stage 3
venture investment, as documented by Raade and Dantas Machado (2008), are more 
prevalent in specific industries.  
Our results suggest that, inasmuch as some of the differences in performance can 
be explained by country-specific factors (in particular, when considering start-up/seed 
and early stage firms), there are also important idiosyncratic differences across industries. 
For instance, firms in the biotech and the medical / health / life science sectors tend to be 
significantly more likely to have a successful exit via IPO, while firms in the computer 
industry and communications and media are more prone to exit via merger or acquisition. 
Important differences across industries also emerge when considering infant versus 
mature firms, and their preferred exit. 
The remainder of this paper is organized as follows: on Section II we provide an 
overview of our data, followed by a description of how we construct the different 
variables associated with success rate on Section III. Section IV takes a first look at the 
empirical results through some summary statistics, while Section V presents the results of 
our regression analysis.  Section VI concludes. 
II. Sample 
Our sample covers the period 1985-2008 and includes data from the U.S. and all EU-15 
countries (Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, 
Luxembourg, the Netherlands, Portugal, Spain, Sweden, and the United Kingdom). The 
source of information on venture capital investment, company count, rounds of 
investment, and outcome/exit is VentureXpert.  Data on country specific variables (Gross 
Domestic Product, Population, and Research and Development figures) stems from 
Euromonitor and the SourceOECD database.  Finally, patent data is obtained from the 
European Patent Office (EPO, for all patent applications made in the EU-15 countries), 
and the U.S. Patent Trade Office (USPTO, for all applications made in the U.S. market). 
  In total, we are able to track the evolution of 51,994 firms that received VC 
funding, and determine the resulting exit – if any – that each of these firms was able to 
achieve. Table A1 in the appendix summarizes the composition of this data set: by 
country, stage of development of the firm when it received its first round of VC funds 
(start-up and seed, early stage, or mature) and by industry; this latter classification is 4
explained in more detail below.  As expected, the U.S. is the predominant country of 
origin of the firms in question (34,088; nearly 2/3 of the entire sample); while we were 
only able to collect information on 65 and 66 firms for Greece and Luxembourg, 
respectively.
  Given that this paper seeks to determine whether industry specific factors play a 
significant role in determining the likelihood for a successful venture exit, it would be of 
great benefit to obtain as many independent industry-specific variables that match to the 
industry categories identified by VentureXpert.  Following Gompers, Kovner, Lerner and 
Scharfstein (2008), we aim at classifying firms into categories that exhibit similarities in 
technology and management expertise.  This task poses a bit of a challenge, given that 
the industry trend data is only available based on standardized codes, of which there are 
many different forms unique to the U.S., the EU overall, and to each of the countries 
within the EU.  
  In order to match the data available in International Standard of Industrial 
Classification (ISIC) codes with the success rates using VentureXpert industry categories, 
we initially mapped out a categorization table of the VentureXpert industry classification 
system from its most broad level ‘Major Group’ down to the most-detailed level titled 
‘Sub category 3’. Then, by evaluating each line of the ISIC category list, we assign them 
to their appropriate VentureXpert Sub Category 3 listing. Table A2 in the Appendix 
presents an overview how this mapping works. The outcome is the classification into 6 
main industry groups: computer software and hardware; semiconductors and other 
electronics; biotechnology; medical, health and life sciences; communications and media;
and non-high technology. This allows us to maintain the main recipients of venture 
capital disbursements (Gompers and Lerner, 2001) separated, while allowing for a 
reasonable degree of aggregation in the data that will assist us in the empirical analysis.  
III. Measuring Success 
Some previous studies that have looked at how to compute returns to VC investment 
include Cumming and MacIntosh (2003), who examine a sample of 248 hand-collected 
VC exits in Canada and the U.S., and Cochrane (2005), who analyzes exits using 
VentureOne data.  In order to measure success of an investment, ideally we would require 5
data on the actual returns on venture capital firm‘s investments.  However, this is not 
possible because neither Venture Economics, nor VentureXpert collect valuation 
information for all of the companies that have been part of a VC investment fund. 
Following Gompers et al. (2008), our proposed measure of ‘success’ takes into 
consideration the type of exit of a particular company.  We define Success by IPO (S1),
as the number of firms that received venture capital investment, and successfully exited 
via IPO.  Success by Acquisition or Merger (S2) is defined analogously, this time 
considering successful VC-sponsored firms that were either acquired or merged with 
other firms.  Finally, we introduce a measure of Overall Success (OS), which adds S1 and 
S2 success and includes in addition the cases in which the companies’ exits took place 
through a leveraged buy-out (LBO). 
We perform one further classification, which consists in separating the 
performance of seed/start-up and early stage firms that received VC funds, from the 
performance of more mature firms. For all company data we recorded whether the firm 
was an early stage or seed/start-up at the time it received its first VC investment.  Success
by Infant Firms (IS) is computed as the number of start-up and seed, and early-stage firms 
funded by VC investment, which successfully exited by going public, through merger or 
acquisition, or by means of a leveraged buy-out.  Similarly, Success by Mature Firms
(MS) is computed as the number of established firms receiving VC funds, and 
successfully exited by any of the above-cited channels. 
The success variables are constructed by analyzing all VC investments, with 
investment domicile determined by company nation.  These are then ordered by country, 
by year and by industry to obtain a success rate, which is defined as the number of VC-
backed companies in a given year for a given country that had a successful exit, divided 
by the total number of VC invested companies for that given year and country. The year 
specified in this case is determined by the year in which the first round investment was 
received. For example, this means that for all companies that received their first round of 
VC financing in the year 2000, their future success would be attributed to that year of 
original investment, in this case 2000. 6
IV. Descriptive  Analysis 
As a first step it is useful to analyze where the difference in success arises from, i.e., to 
look at a simple comparison between the performance of the U.S. and the EU-15 
countries over the period 1985-2008. Table I presents the comparison between the U.S. 
and EU-15 VC investments and success rates. 
Table I 
Comparison between the U.S. and EU-15: Venture Capital and Success by IPO and 
Acquisition or Merger 
Notes: Success by IPO is computed as the number of firms who successfully exited by initial public 
offering divided by the total number of firms receiving venture capital funding. Success by Acquisition or 
Merger is computed as the number of firms who successfully exited by merging with or being acquired by 
other firms, divided by the total number of firms receiving venture capital funding. Overall Success, adds
Success by IPO, Success by Acquisition or Merger, and includes in addition the cases in which the 
companies’ exits took place through a leveraged buy-out (LBO). For all three measures, the rates were 
computed considering all transactions between 1985 and 2008, by industry and country, and were 
multiplied by a factor of 100. 
Number of 
firms receiving 
VC funding 
Success by 
IPO  (in %) 
Success by 
Acquisition or 
Merger (in %) 
Overall 
Success         
(in %)
United States  34,088  13.43 21.94 41.40 
EU-15 17,909  7.70  10.34  38.33 
EU-15 (excl. Greece & Luxembourg)   17,775  7.66  10.40  38.41 
Table I indicates that between 1985 and 2008 nearly twice as many firms received 
VC funding in the U.S. alone then in the whole EU-15 area.  For both the U.S. and the 
Euro Area, exit via merger and acquisition (M&A) is more likely than exit via IPO. As 
documented in previous studies (Black and Gilson (1998), Murray and Marriott (1998), 
and Bottazi and Da Rin (2002)), VC has produced more successful exits in the U.S. then 
in Europe. Particularly, U.S. firms outperform EU-15 firms by a 2-to-1 ratio when it 
comes to both exits by IPO, and via M&A. However, once we include leveraged buy-outs 
(LBOs) as a successful exit, the difference between Europe and the US shrinks 
considerably. But LBOs are not necessarily a desirable outcome. 7
Table II displays the comparison of VC investments and success rates between the 
U.S. and Europe separated for infant and mature firms. 
Table II 
Comparison between the U.S. and EU-15: Venture Capital and Success by Infant 
and Mature Firms 
Notes: Success by Infant Firms is computed as the number of start-up and seed, and early-stage firms who 
successfully exited by going public, merger and acquisition, or leveraged buy-outs, divided by the total 
number of start-up and seed, and early-stage firms which received venture capital funding. Success by 
Mature Firms is computed as the number of established firms who successfully exited by going public, 
merger/acquisition, or leveraged buy-outs, divided by the total number of established firms, which received 
venture capital funding. For both measures, the rates were computed considering all transactions between 
1985 and 2008, by industry and country, and were multiplied by a factor of 100. 
Ex-ante ratio 
(mature firms 
to early stage) 
Success by 
infant firms   
(in %) 
Success by 
mature firms   
(in %) 
Ex-post ratio 
(mature firms 
to early stage)
United  States  1.07 34.50  47.82 1.49 
EU-15  2.74 15.70  46.72 8.14 
EU-15 (excl. Greece & Luxembourg)   2.73  15.63  46.64  8.15 
For the U.S., nearly an equal number of mature vis-à-vis infant firms were 
financed.  On the contrary, for the EU-15, eight out of every 11 firms financed were 
mature firms. Moreover, Table II indicates that success rates are drastically different. 
Consistent with previous findings in the literature early stage and seed and start-up firms 
in Europe largely underperform in comparison to their counterparts in the U.S. (see 
Murray and Marriott (1998) for evidence between 1991 and 1997, and Hege, Palomino 
and Schwienbacher (2009) as well as Raade and Dantas Machado (2008) for more recent 
evidence), while mature VC-backed firms have close to 50 percent probability of success 
both in Europe and the U.S.  
These two above observations combined make for an overwhelming outcome: 
The ratio of successful mature firms to successful infant firms in Europe is over 8-to-1, 
while it is less than 1.5 in the U.S. Therefore, the difference one needs to focus on is not 8
only why VC financing is more successful in the U.S. but why start-up/seed and early-
stage firms are relatively unsuccessful in Europe.  
Before we get to analyze these substantial differences with the help of regression 
analysis, we first investigate whether there are significant differences in performance 
between the six different industries.  From here on forth, we exclude Greece and 
Luxembourg from the analysis, since for some industries there were no transactions 
registered in the case of these two countries. As can be seen from Tables I and II, the size 
effects in terms of total firm count and average success rates from excluding both 
countries are negligible. 
Our empirical findings in Table III prove that the aggregate results are also found 
at an industry-by-industry summary analysis, with just a few exceptions. The U.S. 
outperforms Europe in success by acquisition (significantly for all six industries), and in 
success by IPO (albeit it is only significant for medical, health and life sciences as well as 
for non-high technology and other). Moreover, the U.S. outperforms Europe in success 
by early-stage firms (significantly for all industries), and is similar to Europe in success 
by mature firms (no significant differences for any of the industries). 
Table III also indicates that exit by acquisition has a higher rate of success than 
exit by IPO, except for VC-backed biotech firms.  Exit by IPO, as documented by 
Gompers and Lerner (1998), provides significantly higher returns when compared to 
other types of exit.  The observation that the biotech sector is the “best” performer comes 
to no surprise - as of the last decade, this sector has been identified as one of the thriving 
new industries in the U.S. (see Gordon (2002) as well as Guo, Lev and Zhou (2005)). 
Similarly, in the case of Europe, its characteristics confirm it as one of the most dynamic 
industries; according to Popov and Roosenboom (2009), as of 2005, 55% of biotech 
companies in Europe were less than 5 years old; the rate of new business incorporation 
was 14% on average, 44% of biotech employees in Europe have been actively involved 
in research and development (R&D); and the industry spent 7.5 billion Euro on R&D in 
2004 alone, making it one of the most R&D intensive sectors in Europe. 9
Table III 
Comparison between the U.S. and EU-15: Industry-by-Industry 
Notes: Success by IPO and Success by Acquisition or Merger are computed as the number of firms who 
successfully exited via IPO (merging with or being acquired by other firms, respectively) divided by the 
total number of firms receiving venture capital funding. Success by Infant Firms is computed as the number 
of start-up and seed, and early-stage firms who experienced overall success, divided by the total number of 
start-up and seed, and early-stage firms which received venture capital funding. Success by Mature Firms is
computed as the number of established firms who experienced overall success, divided by the total number 
of established firms, which received venture capital funding. For all measures, the rates were computed 
considering all transactions between 1985 and 2008, by industry and country, and were multiplied by a 
factor of 100. ***, **, and * determine significance at the 1%, 5%, and 10% level, respectively. 
Success by 
IPO (in %) 
Success by 
Acquisition or 
Merger (in %)
Success by 
infant firms   
(in %) 
Success by 
mature firms  
(in %) 
Computer Hardware and Software      
   United States  9.43 27.21  35.34  44.69 
   EU-15 (excl. Greece & Luxembourg)  7.49  11.68  15.77  34.81 
   Test of difference in means (significance)    ***  ***   
Semi- Conductors and Other Electronics      
  United States  13.72 24.35 35.61 52.55 
  EU-15 (excl. Greece & Luxembourg)  7.88  10.72  13.26  45.58 
   Test of difference in means (significance)    **  **   
Biotechnology      
   United States  22.14 16.06 35.74 51.00 
   EU-15 (excl. Greece & Luxembourg)  11.54  9.08  19.96  34.81 
   Test of difference in means (significance)    *  *   
Medical / Health / Life Sciences      
   United States  17.89 19.11 34.30 50.84 
   EU-15 (excl. Greece & Luxembourg)  10.49  9.62  16.02  48.66 
   Test of difference in means (significance)  *  **  *   
Communications and Media      
   United States  13.10 27.47 38.30 48.91 
   EU-15 (excl. Greece & Luxembourg)  8.32  14.02  20.20  39.95 
   Test of difference in means (significance)    **  ***   
Non-High Technology / Other      
   United States  14.74 16.54 27.28 47.95 
   EU-15 (excl. Greece & Luxembourg)  6.96  9.50  11.75  50.72 
   Test of difference in means (significance)  ***  ***  ***   10
It is therefore worthwhile asking: Can we identify any other success story – other 
than venture capital in the biotech industry? Or is it the case, as this first overview 
suggests, that differences in success rates are mainly linked to the Europe-U.S. 
differences, rather than industry-specific characteristics? We attempt to find some 
answers to these questions in our next section, by conducting a more in-depth regression 
analysis in order to control for other explanatory variables. 
V. Regression  Analysis
We empirically investigate in the following which factors are associated with successful 
VC investments by means of multi-variable analysis.  We begin by providing a brief 
discussion as to which indicators serve as a good proxy for determinants we expect to
play a significant role in enhancing the likelihood of a successful exit by a VC-backed 
firm. 
Venture Capital Investment by Industry Group
First of all, it is important to distinguish between funds raised and funds invested. A 
venture capital fund will raise resources each year; however they may not necessarily 
invest those funds in the same year.  VC funds are actively managing current portfolio 
companies until the proper exit time and may not be ready to take on a new investment 
until a current company has exited because of management availability. Likewise, funds 
raised may be inaccurate as a proxy because many times it is simply a roll-over process 
of funds from one project to the next. To explain, when a VC fund exits a portfolio 
company, these funds are then returned to their original investors, who many times 
become repeat clients to the VC fund and reinvest their desired level of capital back into 
the fund, which then represents the way capital is recycled in a VC fund.  Another reason 
why funds raised may not show a logical pattern to actual investment is that VC funds 
may have not found what they consider to be high potential investments, and may decide 
to wait and keep the funds sitting until an opportune venture is found or inquires directly 
by the fund for VC funding assistance.
In contrast, data on VC disbursements is exactly the capital given a designation 
into a venture company, and best represents the activity of VC on the supply side 11
regarding investment level of funds.  This variable can best identify how much capital 
has been put into venture capital-backed companies in each industry and country.  It is 
more interesting to see whether one industry or country is spending more or less in 
relative terms, and moreover how that has played a role in the ability of each portfolio 
company to reach exit stage.   
For our regression analysis we employ the average investment per firm (in 
millions of Euro) per industry and country, over the period 1985-2008.  A priori, one 
would expect that, the larger the amount of resources devoted to a representative firm 
belonging to a particular industry, the more likely it will be that this representative firm 
has a successful exit.   
Gross Domestic Product
A high level of aggregate economic growth might indicate favorable entrepreneurial 
conditions; as periods of increased GDP might indicate that possibilities to 
commercialize technological innovations are increased (see Gompers and Lerner (1998) 
as well as and Jeng and Wells (2000)). In our regressions we need therefore to control for 
aggregate economic activity.  Moreover, since we are using averages over time and not a 
year-by-year analysis, we opt for using average GDP per capita (in thousands of Euro), 
between 1985 and 2008, for each of the countries of interest.  We would expect in general 
that higher GDP per capita should be associated with a higher likelihood of a successful 
VC project.  Since several studies that use cross-country data also control for real GDP 
growth as a determinant of VC investment (Jeng and Wells (2000), Gomes Santana Felix, 
Gulamhussen and Pacheco Pires (2007), among others), we run a separate set of 
regressions employing real growth instead of GDP per capita. The results, which are 
presented in Tables A3 and A4 in the appendix, suggest that our main findings are robust 
to the use of this alternative measure of economic activity.  
Research and Development Expenditures
Venture capital investments are high-risk, high-reward projects, which makes them 
substitutable with R&D investments.  Thus, an increase in domestic expenditure on R&D 
would imply a greater supply of funds available for VC and also demand for similar high-12
tech, high-risk companies. When R&D is better funded, the chances of technological and 
other advanced science opportunities should increase and may dually lead to more VC 
ventures. R&D data are broken down into the following sources of funding: business 
enterprise, government, and their total.  
In expectation, times in which investments in R&D are higher might indicate 
higher technological or innovative opportunities. Besides the idea that R&D spending 
might capture demand effects over time, it might also capture demand effects across 
countries.  In this understanding, countries with higher levels of R&D spending might 
contain a higher number of entrepreneurs with potentially fruitful ideas. This effect has 
been described by Gompers and Lerner (1998) who show for the U.S. that states with 
higher levels of both academic and corporate R&D spending also have higher levels of 
VC financing activity. 
Our analysis controls therefore for aggregate R&D per capita, also for the period 
comprising 1985-2008, for each of the countries in our sample.  All other things equal, a 
larger amount of funds devoted for R&D would be associated with higher technological 
or innovative opportunities, and therefore, higher likelihood of success of VC-financed 
projects.  
Patents
Higher levels of patent applications could be used to indicate higher levels of 
technological opportunities, and thus VC activity. The data seeks to capture how many 
applications are made by each country, regardless of whether the applicant was domiciled 
in that nation or not. Kortum and Lerner (2000) show that venture capital has a higher 
propensity to generate patent applications than does R&D spending. In relation thereto, if 
patent applications are a proxy for innovation, periods or countries with relatively more 
patent applications might indicate higher technological opportunities. On a per country 
basis, higher patenting activity might also indicate a greater willingness to commercialize 
innovations and to protect ones inventions.  13
Industry-specific variables
Our baseline specification for the regression analyses is to model our alternative 
measures of success as a linear function of average investment per firm (in millions of 
Euro); GDP per capita and R&D per capita (both measured in thousands of Euro); and 
the number of patents (per one-thousand inhabitants).  We do so with a sample of 13 
European countries (i.e. EU-15 excluding Greece and Luxembourg, as a result of the 
above-mentioned data limitations), and across the 6 industries of interest.  Given the 
documented differences in performance of VC-funded firms in the U.S. and Europe, we 
run the regressions with and without the U.S., to verify if the main results at the industry 
level still apply. 
To our baseline specifications we also add industry-specific dummy variables to 
test whether there are significant differences between industries in regards to the rates of 
success. Specifically, we will use the non-high tech sector as the benchmark for 
comparison.  This broad sector comprises firms of the following industries: business 
services, agricultural, forestry, financial services, utilities, manufacturing, transportation, 
construction, chemicals and materials, pollution and recycling, industrial equipment, oil 
and gas exploration, consumer products, entertainment and leisure, and food and 
beverage; and it represents 36% and 54% of all firms receiving VC funding for the U.S. 
and the EU-15, respectively.
In a first step, we differentiate between two successful exit strategies: exit via IPO 
and exit via M&A. In the second step, we run separate regressions for infant and mature 
firms. Table IV shows the regression results for all firms with an IPO as a successful exit 
strategy. 
Table IV shows that in case of a successful exit via IPO, the average investment is 
positive and significant for the entire period. All other things equal, a higher level of VC 
funding to a particular industry makes this industry more likely to successfully go public. 
We also see that for exit via IPO the level of GDP per capita matters: it is positive and 
significant at 5% for all specifications. Interestingly and contrary to our expectations and 
previous studies, the level of R&D investments is not significant. 14
Table IV 
Success 1: Exit via IPO 
Notes: Successful Exit via IPO is computed as the number of firms who successfully exited by going 
public, divided by the total number of firms receiving venture capital funding, between 1985 and 2008, by 
industry and country, multiplied by a factor of 100. Average investment per firm is measured in millions of 
Euro. GDP per capita and R&D per capita are measured in thousands of Euro. The number of patents is 
per 1,000 inhabitants. Robust standard errors are in parentheses. ***, **, and * determine significance at 
the 1%, 5%, and 10% levels, respectively. 
Baseline       
(all countries) 
Baseline      
(excl. U.S.) 
Industry-specific  
(all countries) 
Industry-specific 
(excl. U.S.)
Average investment per firm  0.330*** 
(0.076)
0.327*** 
(0.102)
0.307*** 
(0.069)
0.288*** 
(0.097)
GDP per capita  0.225** 
(0.108)
0.231** 
(0.108)
0.224** 
(0.109)
0.233** 
(0.109)
R&D per capita  5.357 
(4.769)
5.275 
(4.674)
5.801 
(4.610)
5.971 
(4.659)
Patents -0.631 
(0.437)
-0.724* 
(0.433)
-0.644 
(0.457)
-0.779* 
(0.473)
Computer Hardware and Software      0.162 
(0.888)
0.403 
(0.935)
Semi-Conductors / Other Electronics      -0.670 
(1.171)
-0.577 
(1.262)
Biotechnology     3.079* 
(1.749)
2.677 
(1.780)
Medical / Health / Life Sciences      2.269* 
(1.208)
2.110* 
(1.240)
Communications and Media      0.705 
(1.501)
1.173 
(1.563)
        
Adjusted R-squared  0.361 0.283  0.428  0.341 
No. of Observations  84  78  84  78 15
     Table IV indicates that if we exclude the U.S. from the sample, patents become 
marginally significant, albeit with a negative sign. With respect to the non high-tech 
sector, VC investment in biotech is more likely to result in an IPO. It contains a 3 percent 
higher success rate via an IPO, after controlling for other variables. It is significant with 
the U.S., but once we exclude the U.S. from our sample, the coefficient becomes smaller 
and no longer significant at the 10% level. 
Firms receiving VC funds in the medical, health, and life sciences industry are 
also more likely to exit via IPO (2 percent higher success rate), while the effect remains 
similar if we exclude the U.S. from the sample. Finally, all other industries do not 
significantly differ from the non high-tech sector.
Table V shows that in the case of a successful exit via a merger or an acquisition, 
the average investment is again positive and significant. This result holds for all 
specifications and all measures of success. It is also interesting to see that none of the 
country-specific control variables help in explaining a more successful exit via M&A. 
Excluding the U.S. from the analysis does not affect any of the results. However, it does 
lower considerably the explanatory power and it cuts in almost half the coefficient on 
average investment. 
VC-backed firms in the Computer Hardware and Software industry are more 
likely to exit via merger and acquisition (3.2 percent) than our control group of non high-
tech and other firms. After controlling for funds and other variables, this finding still 
holds. Dropping the U.S. from our sample reduces the coefficient to 2.2 percent, but it is 
still significant at the 5% level. Firms in the Communications and Media industry are also 
more likely to exit via M&A: 5.3 to 5.4 percent, i.e. the results prove to be robust to 
either with or without the U.S. On the other hand, biotech appears to be the opposite 
story: it is less likely to exit a VC-backed biotech firm via M&A in comparison to the 
non high-tech sector. Firms of the other two industries, Semi-conductors and other 
electronics as well as medical, health, and life sciences, show no significantly different 
likelihood of a successful exit. 16
Table V 
Success 2: Exit via Acquisition or Merger 
Notes: Successful Exit via Acquisition or Merger is computed as the number of firms who successfully 
exited by merging with or being acquired by other firms, divided by the total number of firms receiving 
venture capital funding, between 1985 and 2008, by industry and country, multiplied by a factor of 100. 
Average investment per firm is measured in millions of Euro. GDP per capita and R&D per capita are 
measured in thousands of Euro.  The number of patents is per 1,000 inhabitants. Robust standard errors are 
in parentheses. ***, **, and * determine significance at the 1%, 5%, and 10% levels, respectively. 
Baseline      
(all countries) 
Baseline    
(excl. U.S.) 
Industry-specific
(all countries) 
Industry-specific 
(excl. U.S.)
Average investment per firm  0.355*** 
(0.078)
0.167** 
(0.069)
0.374*** 
(0.077)
0.215*** 
(0.076)
GDP per capita  0.089 
(0.216)
0.120 
(0.210)
0.089 
(0.179)
0.118 
(0.172)
R&D per capita  -0.359 
(5.980)
2.513 
(5.529)
-0.729 
(4.264)
1.647 
(4.354)
Patents 0.273 
(0.441)
-0.309 
(0.417)
0.284 
(0.408)
-0.240 
(0.419)
Computer Hardware and Software      3.153*** 
(1.196)
2.194** 
(0.936)
Semi-Conductors / Other Electronics      1.912 
(1.692)
1.638 
(1.770)
Biotechnology     -2.453*** 
(0.960)
-2.328** 
(1.022)
Medical / Health / Life Sciences      -1.491 
(1.315)
-1.648 
(1.379)
Communications and Media      5.342*** 
(1.883)
5.448*** 
(1.868)
        
Adjusted R-squared  0.265 0.068 0.472  0.338 
No. of Observations  84  78  84  78 17
     In the following we also investigate whether the life-cycle of the VC-backed firms 
might play a pivotal role in the determination of successful exits. Table VI presents our 
findings of successful exits of infants firms. 
Table VI indicates that the average investment has a positive and significant 
correlation with success of start-up/seed and early-stage firms. Interestingly, neither 
R&D, nor GDP per capita contribute towards explaining a more successful exit of start-
up/seed and early-stage firms. Patents have a negative and significant correlation with 
success for infant firms – only when excluding the U.S. from the data. All industries 
(except Semi-conductors / other electronics) exhibit positive and significantly higher 
likelihood of success of start-up/seed and early-stage firms, when compared to the non 
high-tech sector. The empirical findings in Table VI also show that excluding the U.S. 
from the regression analysis does not affect any of the results.
Table VII presents our empirical findings for the regressions analysis of 
successful exits of mature firms. The results show that average investment is again 
positive and significant for all specifications. The level of R&D investments only matters 
when controlling for industry-specific effects and when the U.S. is included in the 
sample. Moreover, GDP per capita and patents help in explaining a more successful exit 
of mature firms. As expected, our empirical findings in Table VII quite mirror the image 
of the previous results of infant firms. All industries are less likely to experience a 
successful exit by mature firms, when compared to the non high-tech sector. In the case 
of the medical, health, and life-science industry as well as for communications and 
media, the coefficients are negative, but not statistically significant. 18
Table VI 
Successful Exit of Infant Firms 
Notes: Successful Exit of Infant Firms is computed as the number of start-up and seed, and early-stage 
firms who successfully exited by going public, merger, acquisition, or leveraged buy-outs, divided by the 
total number of start-up and seed, and early-stage firms which received venture capital funding, between 
1985 and 2008, by industry and country; multiplied by a factor of 100. Average investment per firm is 
measured in millions of Euro. GDP per capita and R&D per capita are measured in thousands of Euro. 
Robust standard errors are in parentheses. ***, **, and * determine significance at the 1%, 5%, and 10% 
levels, respectively. 
Baseline      
(all countries) 
Baseline    
(excl. U.S.) 
Industry-specific
(all countries) 
Industry-specific 
(excl. U.S.)
Average investment per firm  0.756*** 
(0.124)
0.530*** 
(0.141)
0.712*** 
(0.140)
0.463*** 
(0.164)
GDP per capita  0.044 
(0.319)
0.088 
(0.314)
0.044 
(0.306)
0.091 
(0.298)
R&D per capita  6.693 
(7.644)
10.004 
(7.971)
7.539 
(7.380)
11.198 
(7.778)
Patents -0.527 
(0.679)
-1.327* 
(0.795)
-0.553 
(0.641)
-1.422* 
(0.728)
Computer Hardware and Software      6.393*** 
(1.958)
5.601*** 
(1.978)
Semi-Conductors / Other Electronics      4.853 
(3.355)
4.888 
(3.542)
Biotechnology     6.988*** 
(2.415)
7.260*** 
(2.720)
Medical / Health / Life Sciences      5.857* 
(3.229)
5.960* 
(3.260)
Communications and Media      10.896*** 
(2.413)
11.834*** 
(2.463)
        
Adjusted R-squared  0.309 0.142 0.405  0.285 
No. of Observations  84  78  84  78 19
Table VII 
Successful Exit of Mature Firms 
Notes: Successful Exit of Mature Firms is computed as the number of established firms who 
successfully exited by going public, merger/acquisition, or leveraged buy-outs, divided by the 
total number of established firms which received venture capital funding, between 1985 and 
2008, by industry and country; multiplied by a factor of 100. Average investment per firm is 
measured in millions of Euro. GDP per capita and R&D per capita are measured in thousands of 
Euro.  The number of patents is per 1,000 inhabitants. Robust standard errors are in parentheses. 
***, **, and * determines significance at the 1%, 5%, and 10% level, respectively. 
Baseline      
(all countries) 
Baseline    
(excl. U.S.) 
Industry-specific
(all countries) 
Industry-specific 
(excl. U.S.)
Average investment per firm  0.671*** 
(0.155)
0.776*** 
(0.233)
0.672*** 
(0.169)
0.829*** 
(0.276)
GDP per capita  -0.261 
(0.430)
-0.271 
(0.426)
-0.261 
(0.388)
-0.274 
(0.376)
R&D per capita  16.246 
(11.905) 
14.489 
(12.177) 
16.239* 
(8.687)
13.526 
(5.687)
Patents -0.706 
(1.175)
-0.484 
(1.255)
-0.706 
(0.884)
-0.407 
(0.919)
Computer Hardware and Software      -12.053*** 
(2.619)
-12.880*** 
(2.660)
Semi-Conductors / Other Electronics      -6.590* 
(3.833)
-7.453* 
(3.968)
Biotechnology     -14.779*** 
(5.181)
-16.834*** 
(5.586)
Medical / Health / Life Sciences      -4.722 
(3.717)
-5.899 
(3.942)
Communications and Media      -5.282 
(3.593)
-5.409 
(3.765)
        
Adjusted R-squared  0.181 0.142 0.325  0.317 
No. of Observations  84  78  84  78 20
Summarizing our main results we find that in all specifications, the average 
amount of funding VC-backed firms receive is a robust and consistent predictor of the 
likelihood of success. This holds for any type of exit (whether via IPO, M&A, or overall 
success) but also for when we separate firms into by the stage in which initial investment 
takes places (infant and mature). 
More interestingly, different industries do exhibit different patterns in regards to 
their rate of success: firms in the biotech and the medical, health, and life science 
industry tend to be significantly more likely to have a successful exit via IPO, while firms 
in the computer industry and communications and media are more prone to exit via 
merger or acquisition.  
VI. Conclusions 
Success in VC-funded firms clearly depends on a wide array of factors, many of them 
quite specific. The contribution of this paper consists in attempting to identify general 
conditions under which enterprises belonging to certain industries in distinct countries 
can achieve a higher likelihood of a desirable exit. 
Our findings allow us to argue that differences in the rates of success may only 
partly be due to the intrinsic differences between the European and U.S. VC experiences. 
Industry-specific characteristics also play an important role – in particular, our results 
suggest that the relatively higher success rate found in VC-funded biotech firms, for 
instance, may be mostly due to the intrinsic dynamic nature of this sector, and less to 
where the firms are located and where the funds come from. 
We also observe – confirming the findings of previous studies – that differences 
in the stage at which firms received VC funding tends to be a crucial determinant of 
success – mainly for European countries. 
Finally, we recognize that this constitutes only a first step towards explaining 
differences in rates of success and types of exits. Other factors, such as the degree of 
experience of venture capital organizations (Gompers et al, 2008), and other industry-
specific characteristics, need to be controlled for to draw more definite conclusions.   
These and other extensions are on our sights for future research.21
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Appendix Table A3 
Success by Exit via IPO and M&A, controlling by GDP growth 
Notes: Success by IPO and Success by M&A are computed as the number of firms who successfully exited 
via IPO (merging with or being acquired by other firms, respectively) divided by the total number of firms 
receiving venture capital funding, between 1985 and 2008, by industry and country, multiplied by a factor 
of 100. Average investment per firm is measured in millions of Euro. Real GDP growth takes the average 
growth rate over the period 1985-2007 multiplied by a factor of 100, while R&D per capita is measured in 
thousands of Euro.  The number of patents is per 1,000 inhabitants. Robust standard errors are in 
parentheses. ***, **, and * determine significance at the 1%, 5%, and 10% levels, respectively. 
Success by IPO 
(all countries) 
Success by IPO   
(excl. U.S.)
Success by 
M&A 
(all countries) 
Success by 
M&A       
(excl. U.S.)
Average investment per firm  0.308*** 
(0.070)
0.276*** 
(0.097)
0.370*** 
(0.072)
0.250*** 
(0.078)
Real GDP growth  -0.765 
(0.521)
-0.900* 
(0.532)
1.968*** 
(0.562)
1.681*** 
(0.561)
R&D per capita  9.140* 
(4.568)
9.590** 
(4.513)
2.306 
(3.701)
4.256 
(3.794)
Patents -0.603 
(0.454)
-0.780* 
(0.462)
0.406 
(0.372)
-0.007 
(0.383)
Computer Hardware and Software  0.164 
(0.806)
0.389 
(0.831)
3.145*** 
(1.120)
2.235** 
(0.888)
Semi-Conductors / Other Electronics  -0.671 
(1.122)
-0.569 
(1.201)
1.915 
(1.616)
1.612 
(1.712)
Biotechnology  3.076* 
(1.709)
2.707 
(1.728)
-2.443*** 
(0.956)
-2.420** 
(1.014)
Medical / Health / Life Sciences  2.267* 
(1.294)
2.133 
(1.332)
-1.484 
(1.241)
-1.716 
(1.309)
Communications and Media  0.703 
(1.495)
1.189 
(1.551)
5.351*** 
(1.801)
5.401*** 
(1.822)
      
Adjusted R-squared  0.421 0.338 0.553 0.419 
No. of Observations  84  78  84  78 28
Appendix Table A4 
Success by Stage of Funding, controlling by GDP growth 
Notes: Success by Infant Firms and Success by Mature Firm are computed as the number of start-up and 
seed, and early-stage firms (mature firms, respectively), who successfully exited by going public, merger 
and acquisition, or leveraged buy-outs, divided by the total number of start-up and seed, and early-stage 
firms (mature firms, respectively) which received venture capital funding, between 1985 and 2008, by 
industry and country, multiplied by a factor of 100. Average investment per firm is measured in millions of 
Euro.  Real GDP growth takes the average growth rate over the period 1985-2007 multiplied by a factor of 
100, while R&D per capita is measured in thousands of Euro. The number of patents is per 1,000 
inhabitants. Robust standard errors are in parentheses. ***, **, and * determine significance at the 1%, 5%, 
and 10% level, respectively. 
Success of 
Infant firms    
(all countries)
Success of 
Infant firms     
(excl. U.S.)
Success of 
Mature firms   
(all countries) 
Success of 
Mature firms      
(excl. U.S.)
Average investment per firm  0.710*** 
(0.139)
0.476*** 
(0.171)
0.680*** 
(0.165)
0.762*** 
(0.276)
Real GDP growth  1.171 
(1.029)
0.586 
(1.508)
-3.242** 
(1.476)
-3.230** 
(1.618)
R&D per capita  9.178 
(7.614)
12.959* 
(7.700)
9.263 
(8.397)
7.709 
(8.012)
Patents -0.484 
(0.657)
-1.320* 
(0.753)
-0.945 
(0.859)
-0.872 
(0.945)
Computer Hardware and Software  6.388*** 
(1.923)
5.616*** 
(1.963)
-12.041*** 
(2.371)
-12.969*** 
(2.443)
Semi-Conductors / Other Electronics  4.855 
(3.296)
4.878 
(3.477)
-6.596* 
(3.486)
-7.403** 
(3.664)
Biotechnology  6.994*** 
(2.488)
7.225*** 
(2.762)
-14.796*** 
(4.961)
-16.653*** 
(5.407)
Medical / Health / Life Sciences  5.861* 
(3.243)
5.933* 
(3.302)
-4.734 
(3.573)
-5.765 
(3.857)
Communications and Media  10.902*** 
(2.280)
11.815*** 
(2.397)
-5.299 
(3.399)
-5.316 
(3.578)
        
Adjusted R-squared  0.414 0.287 0.368  0.360 
No. of Observations  84 78 84  78 CFS Working Paper Series: 
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